Mesoblast LimitedASX: MSB

Mesoblast Board Changes

· Issued by Mesoblast Limited via ASX

Filed with ASX · · 2 pages · English

Summary by 6ix AI

Mesoblast Limited announced changes to its Board, including the retirement of certain members and plans to recruit new directors with global commercial experience in the biopharmaceutical sector. The company is now a revenue-generating enterprise following the successful launch of Ryoncil in the United States, and aims to enhance its Board to support future growth.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/mesoblast-board-changes

Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings Call

Release

MESOBLAST BOARD CHANGES New York, USA: November 1 and Melbourne, Australia: November 2, 2026: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced rotational changes and retirement of certain members of its Board, and...

Mesoblast Limited on 6ix

Story so far

Earlier from Mesoblast

Later from Mesoblast

All Mesoblast news releases